Analyzing RYTHM (NASDAQ:RYM) and Assembly Biosciences (NASDAQ:ASMB)Defense World · Oct 6, 2026
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026GlobeNewsWire · Oct 5, 2026
Best Momentum Stocks to Buy for September 17thZacks Investment Research · Sep 17, 2026
New Strong Buy Stocks for September 17thZacks Investment Research · Sep 17, 2026
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 10, 2026
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive PicksZacks Investment Research · Sep 9, 2026Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.72 | -$0.20 | Beat |
| May 7, 2026 | -$0.73 | -$0.54 | Beat |
| Mar 19, 2026 | -$0.51 | $2.48 | Beat |
| Nov 10, 2025 | -$0.50 | -$0.72 | Miss |
| Aug 6, 2025 | -$0.65 | -$1.33 | Miss |
| May 8, 2025 | -$2.01 | -$1.17 | Beat |